Mechanisms of Action for Antifungal Classes and Clinical Use
Overview of Antifungal Drug Classes
Antifungal agents are divided into four main classes based on their molecular targets, each with distinct mechanisms that determine their clinical applications and spectrum of activity 1, 2.
Polyenes (Amphotericin B)
Mechanism of Action
- Polyenes bind directly to ergosterol in the fungal cell membrane, creating pores that cause cell death through leakage of intracellular contents 1, 3.
- This mechanism provides broad-spectrum fungicidal activity against most pathogenic fungi 4.
Clinical Use
- Liposomal amphotericin B (3-5 mg/kg daily) serves as an alternative for systemic candidiasis when echinocandins cannot be used, particularly for C. glabrata infections 5.
- Preferred for C. parapsilosis infections as initial therapy alongside fluconazole 5.
- Reserved for patients with echinocandin intolerance or when other antifungals are unavailable 5.
Key Limitation
- Associated with severe nephrotoxicity and infusion-related reactions, which historically limited its use despite being considered a hallmark treatment since the 1950s 1.
Azoles (Fluconazole, Voriconazole, Newer Triazoles)
Mechanism of Action
- Azoles inhibit ergosterol synthesis by blocking the fungal cytochrome P450 enzyme 14α-demethylase, depleting ergosterol from the cell membrane 3, 6.
- This produces fungistatic activity against susceptible organisms 6.
Clinical Use
- Fluconazole is preferred for C. parapsilosis infections as initial therapy 5.
- Voriconazole is recommended for C. krusei infections when additional mold coverage is desired 5.
- Critically important: azoles should NOT be used as first-line therapy in critically ill patients with systemic candidiasis, as echinocandins demonstrate superior outcomes 5.
- Avoid empiric azole use in patients who received azole prophylaxis due to high likelihood of resistance 5.
Key Limitation
- Extensive drug-drug interactions due to cytochrome P450 inhibition 4.
- Rising resistance, particularly in patients with prior azole exposure 5.
Echinocandins (Caspofungin, Micafungin, Anidulafungin)
Mechanism of Action
- Echinocandins inhibit β-1,3-D-glucan synthase, blocking synthesis of fungal cell wall polysaccharides, representing a novel mechanism targeting a structure absent in mammalian cells 3, 1.
- This provides fungicidal activity against Candida species 2.
Clinical Use
- Echinocandins are the first-line treatment for most patients with systemic candidiasis, particularly those who are critically ill, have recent azole exposure, or are at risk for fluconazole-resistant species 5.
Specific dosing:
- Caspofungin: 70 mg loading dose, then 50 mg daily 5
- Micafungin: 100 mg daily 5
- Anidulafungin: 200 mg loading dose, then 100 mg daily 5
Species-specific considerations:
- Strongly preferred for C. glabrata infections due to intrinsic azole resistance patterns 5.
- For C. parapsilosis, continuation of echinocandin is reasonable if already receiving and clinically stable, though fluconazole or amphotericin B are preferred initially due to higher MICs 5.
- Recommended for C. krusei alongside amphotericin B or voriconazole 5.
Key Advantage
- Superior safety profile compared to polyenes, with minimal drug-drug interactions 4.
Pyrimidine Analogues (Flucytosine)
Mechanism of Action
- Flucytosine is converted intracellularly to 5-fluorouracil, which inhibits fungal DNA and RNA synthesis by interfering with thymidylate synthetase 3.
- Provides fungistatic activity but rapid resistance develops when used as monotherapy 2.
Clinical Use
- Primarily used in combination therapy for cryptococcal meningitis and severe Candida infections 4.
- The ECOFF for flucytosine against C. auris is 0.5 mg/L 7.
Key Limitation
- Bone marrow suppression and requires therapeutic drug monitoring 4.
Allylamines (Terbinafine)
Mechanism of Action
- Terbinafine inhibits squalene epoxidase, blocking ergosterol synthesis and causing toxic accumulation of intracellular squalene 6.
- This dual mechanism provides fungicidal activity 6.
Clinical Use
- Primarily used for dermatophyte infections and onychomycosis 6.
- Limited role in systemic fungal infections 2.
Critical Clinical Principles
Essential Concurrent Interventions
- Remove all central venous catheters in candidemia patients, as catheter retention significantly worsens outcomes 5.
- Perform susceptibility testing for azoles on all bloodstream Candida isolates 5.
- Consider echinocandin susceptibility testing in patients with prior echinocandin exposure or C. glabrata/C. parapsilosis infections 5.
Duration of Therapy
- Continue treatment for 2 weeks after documented blood culture clearance, symptom resolution, and neutropenia resolution (if applicable) 5.
Common Pitfalls to Avoid
- Never assume all Candida species have identical susceptibility patterns—species identification is essential 5.
- Do not stop therapy prematurely; ensure full 2-week course after blood culture clearance 5.
- Avoid relying on fluconazole in critically ill patients where echinocandins are superior 5.
Emerging Resistance Concerns
The development of antifungal resistance represents a significant global threat, with C. auris demonstrating variable resistance to amphotericin B and echinocandins across different clades 7. Most C. auris isolates are fluconazole-resistant, necessitating careful MIC interpretation using validated methods 7. Novel therapeutic strategies including antifungal peptides, nanotechnology, and immunotherapy are under investigation to address these challenges 8, 9, 10.